Cholestasis

SAN DIEGO — Livdelzi appeared safe and well-tolerated and reduced markers of cholestasis and liver injury in patients with primary biliary cholangitis, including those with compensated cirrhosis, according to a presenter.

Although both patient frailty and type of procedure affected outcomes among adults older than 65 years undergoing emergency surgery, the level of procedure risk had a stronger link to adverse outcomes, according to researchers.

BOSTON — After 52 weeks, elafibranor achieved biochemical response and improved symptoms of pruritus in patients with primary biliary cholangitis, according to late-breaking data presented at The Liver Meeting.

Mirum Pharmaceuticals announced the European Commission has approved Livmarli for the treatment of cholestatic pruritis in patients with Alagille syndrome.

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.

WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.

Patients with nonalcoholic fatty liver disease and liver-involved fibrosis frequently had a cholestatic pattern that increased the risk for liver-related events, according to a presentation at The Liver Meeting Digital Experience.

In a video exclusive, Marlyn Mayo, MD, of the University of Texas Southwestern Medical Center, reported long-term treatment with seladelpar was safe and well-tolerated in reducing markers of cholestasis and hepatocellular injury.

In a video exclusive, Lorenzo D’Antiga, MD, Pappa Giovanni XXIII Hospital, said Bylvay induced a sustained improvement in cholestasis-related parameters in patients with progressive familial intrahepatic cholestasis.

Patients with drug-indued liver injury had a long hospital stay, low morbidity and high mortality, according to a study published in the British Journal of Clinical Pharmacology.